NextCure, Inc. announced the publication of a paper titled Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-ß signaling enables PD-L1-mediated tumor eradication in the Journal of Clinical Investigation. This publication outlines data from a preclinical study on the impact of collagens in the extracellular matrix (ECM) on tumor immune infiltration, immune cell activation and anti-tumor responses. The study investigated the effect of targeting collagens in the tumor microenvironment (TME) that signal through the inhibitory leukocyte-associated immunoglobin-like receptor-1 (LAIR-1) in combination with targeting TGF-ß and programmed cell death ligand 1 (PD-L1) in murine models of cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.53 USD | +2.68% | +13.33% | +34.21% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.21% | 42.8M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- NXTC Stock
- News NextCure, Inc.
- NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation